- Home
- MYGN vs UXIN Comparison
MYGN vs UXIN Comparison
Compare MYGN & UXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYGN | UXIN |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.5M | 738.1M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MYGN | UXIN |
|---|---|---|
| Price | $6.48 | $3.82 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $11.82 | N/A |
| AVG Volume (30 Days) | ★ 969.5K | 239.0K |
| Earning Date | 11-03-2025 | 12-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.85 |
| Revenue | ★ $825,300,000.00 | $395,809,853.00 |
| Revenue This Year | $0.08 | $727.65 |
| Revenue Next Year | $5.28 | N/A |
| P/E Ratio | ★ N/A | $4.19 |
| Revenue Growth | 0.21 | ★ 73.08 |
| 52 Week Low | $3.76 | $2.45 |
| 52 Week High | $15.47 | $5.41 |
Technical Indicators
Market Signals| Indicator | MYGN | UXIN |
|---|---|---|
| Relative Strength Index (RSI) | 39.01 | 65.49 |
| Support Level | $6.38 | $3.40 |
| Resistance Level | $6.89 | $4.15 |
| Average True Range (ATR) | 0.29 | 0.32 |
| MACD | -0.06 | 0.11 |
| Stochastic Oscillator | 5.71 | 75.79 |
Price Performance
Historical ComparisonAbout MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About UXIN Uxin Limited ADS
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.